Immunity, Inflammation and Disease
© John Wiley & Sons Ltd
Each article is made available under the terms of the Creative Commons Attribution License
Editor-in-Chief Dr. Marc Veldhoen, Institute for Molecular Medicine, University of Lisbon, Portugal
Online ISSN: 2050-4527
Ethical Policy and Guidelines
Immunity, Inflammation and Disease encourages its contributors and reviewers to adopt the standards of the International Committee of Medical Journal Editors. The Editors reserve the right to reject a paper that does not meet these standards.
Immunity, Inflammation and Disease will not consider papers that have been accepted for publication or published elsewhere. Copies of existing manuscripts with potentially overlapping or duplicative material should be submitted together with the manuscript, so that the Editors can judge suitability for publication.
For more detailed ethical guidelines please visit: https://authorservices.wiley.com/bauthor/publicationethics.asp
All Immunity, Inflammation and Disease papers are checked for potential plagiarism using CrossCheck plagiarism detection software. By submitting your manuscript to Immunity, Inflammation and Disease you accept that your manuscript will be screened for plagiarism against previously published works.
Immunity, Inflammation and Disease – steps to publication
1. Submit or confirm your submission at http:mc.manuscriptcentral.com/iid.
2. We will send you an email confirmation of your submission details.
3. After review and acceptance, you will be prompted to sign the Open Access Agreement form at http:mc.manuscriptcentral.com/iid. Payment of the article publication charge will be required. You can then track the progress of your article through Wiley Author Services.
4. You will receive notification that your proof is ready for review, and be able to make corrections to your article.
5. Your article will publish on Wiley Online Library. If you have previously signed up for alerts through Wiley’s Author Services, you will be sent an email when your article is published online.
You will be prompted to sign the Open Access Agreement electronically after manuscript review and acceptance. We have introduced a convenient new process for signing your Open Access Agreement electronically (eOAA) that will save you considerable time and effort. The author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper. You may preview the copyright terms and conditions here.
Dr. Marc Veldhoen
Address correspondence to the Editorial Office: IIDeditorial@wiley.com
The Journal requires that authors submit electronically via the online submission site at http://mc.manuscriptcentral.com/iid
• Original research articles
• Review articles
• Methods Papers
Manuscripts must be submitted in grammatically correct English. Manuscripts that do not meet this standard cannot be reviewed. Authors for whom English is a second language may wish to consult an English-speaking colleague or consider having their manuscript professionally edited before submission to improve the English. A list of independent suppliers of editing services can be found at http://authorservices.wiley.com/bauthor/english_language.asp. All services are paid for and arranged by the author, and use of one of these services does not guarantee acceptance or preference for publication. A manuscript is considered for review and possible publication on the condition that it is submitted solely to Immunity, Inflammation and Disease, and that the manuscript or a substantial portion of it is not under consideration elsewhere.
We place very few restrictions on the way in which you prepare your article, and it is not necessary to try to replicate the layout of the journal in your submission. We ask only that you consider your reviewers by supplying your manuscript in a clear, generic and readable layout, and ensure that all relevant sections are included. Our production process will take care of all aspects of formatting and style. The list below can be used as a checklist to ensure that the manuscript has all the information necessary for successful publication.
• Title page, including title, authors’ names, authors’ affiliations, and contact details (especially email address) for the person to whom the proof notification is to be sent.
• Structured abstract and 4–6 keywords
• Text (introduction, materials and methods, results, discussion)
• Literature cited (see below for tips on references)
• Tables (may be sent as a separate file if necessary)
• Figure legends
• Acknowledgements, including details of funding bodies with grant numbers
A structured abstract containing an introduction, methods, results, conclusions, and three keywords is required.
CD nomenclature is to be used for all cell differentiation antigens, with or without alternative names which give information about the molecules function. Complement receptors should be named CR1 etc., followed by the correct CD terminology in parentheses: CR1 (CD35); CR2 (CD21); CR3 (CDllb, CD18); CR4 (CDllc, CD18).
Units and Abbreviations
The journal recognizes the adoption of the Système International d'Unitès (SI Units) proposed in Units, Symbols and Abbreviations (1972) published by the Royal Society of Medicine, 1 Wimpole Street, London WIM 8AE, UK. Other abbreviations should be used only for unwieldy names and only when they occur frequently. Where such non-standard abbreviations are used, a glossary should be provided.
As with the main body of text, the completeness and content of your reference list is more important than the format chosen. A clear and consistent, generic style will assist the accuracy of our production processes and produce the highest quality published work, but it is not necessary to try to replicate the journal’s own style, which is applied during the production process. If you use bibliographic software to generate your reference list, select a standard output style, and check that it produces full and comprehensive reference listings. A guide to the minimum elements required for successful reference linking appears below. The final journal output will use the ‘Vancouver’ style of reference citation. If your manuscript has already been prepared using the ‘Harvard’ system, we are quite happy to receive it in this form. We will perform the conversion from one system to the other during the production process.
Minimum Reference Information
• Author(s) in full
• Year of publication
• Article title
• Journal title (preferably not abbreviated)
• Volume number
• Issue number
• Page range
• Author(s) in full
• Year of publication
• Book title
• Place of publication
• No. Pages
• Author(s) in full
• Year of publication
• Chapter title
• Book Author/Editor
• Book title
• Place of publication
• Page range
References to online research articles should always include a DOI, where available. When referring to other Web pages, it is useful to include a date on which the resource was accessed.
All tables must be cited in the text in the order that they should appear.
All figures must be cited in the text in the order that they should appear. Illustrations are an important medium through which to convey the meaning in your article, and there is no substitute for preparing these to the highest possible standard. Therefore, please create your illustrations carefully with reference to our graphics guidelines (see http://authorservices.wiley.com/bauthor/illustration.asp). It is very difficult to improve an image that has been saved or created in an inappropriate format. We realize that not everyone has access to high-end graphics software, so the following information may help if you are having difficulty in deciding how to get the best out of the tools at your disposal.
1. Check your software options to see if you can ‘save as’ or ‘export’ using one of the robust, industry-standard formats. These are:
• Encapsulated PostScript (EPS)
• Tagged Image File Format (TIFF)
• Portable Network Graphics (PNG)
• Portable Document Format (PDF)
2. As a general rule of thumb, images that contain text and line art (graphs, charts, maps, etc.) will reproduce best if saved as EPS or PDF. If you choose this option, it is important to remember to embed fonts. This ensures that any text reproduces exactly as you intend.
3. Images that contain photographic information are best saved as TIFF or PNG, as this ensures that all data are included in the file. JPEG (Joint Photographic Experts Group) should be avoided if possible, as information is lost during compression; however, it is acceptable for purely photographic subjects if the image was generated as a JPEG from the outset (many digital cameras, for example, output only in JPEG format).
4. If you are not sure which format would be the best option, it is always best to default to EPS or PDF as these are more likely to preserve the high-quality characteristics of the original.
5. Microsoft Office. If you have generated your images in Microsoft Office software (Word, Excel, PowerPoint), or similar, it is often best simply to send us the files in their native file formats.
6. Please ensure all images are a minimum of 600 dpi.
Immunity, Inflammation and Disease encourages you to propose one of the figures in your paper as a possible online journal cover, and for potential publication on the official blog of Wiley Open Access: http://wileyopenaccess.wordpress.com
The metric system should be used for all measurements, weights, etc. Temperatures should be expressed in degrees Celsius (centigrade).
Supporting Information and Data Deposition
Supporting Information can be a useful way for an author to include important but ancillary information with the online version of an article. Examples of Supporting Information include additional tables, data sets, figures, movie files, audio clips, 3D structures, and other related nonessential multimedia files. Supporting Information should be cited within the article text, and a descriptive legend should be included. It is published as supplied by the author, and a proof is not made available prior to publication; for these reasons, authors should provide any Supporting Information in the desired final format.
For further information on recommended file types and requirements for submission, please visit: http://authorservices.wiley.com/bauthor/suppinfo.asp.
It is the policy of Immunity, Inflammation and Disease that sequence data must be deposited in the EMBL/GenBank/DDBJ Nucleotide Sequence Data Libraries, the accession number cross-referenced in the published manuscript, and the data made fully available at the time of publication. It is only necessary to submit to one database. The suggested wording for referring to accession-number information is: ‘These sequence data have been submitted to the DDBJ/eMBL/ GenBank databases under accession number U12345’. Details of data submission can be found at: DDBJ/DNA Data Bank of Japan: http://www.ddbj.nig.ac.jp. EMBL: www.ebi.ac.uk. GenBank: http://www.ncbi.nlm.nih.gov
Microarray datasets should be presented in compliance with current practices (see, for example, (MGeD Society at http://www.mged.org/) and deposited in an accredited data base such as Array express (http://www.ebi.ac.uk/microarray-as/ae/) or GEO (http://www.ncbi.nlm.nih.gov/geo/). The corresponding reference to the database entry should be included in the text.
Flow cytometry experiments should be MIFlowCyt (Minimum Information about a flow cytometry experiment) compliant. See www.isac-net.org (in particular the documents www.isac-net.org/media/standards/miflowcyt/MIFlowCyt_080221.pdf and www.isac-net.org/media/standards/miflowcyt/latest.pdf), http://flowcyt.sourceforge.net/ or www.mibbi.org/ for further information.
Protein sequences, which have been determined by direct sequencing of the protein, must be submitted to SWISS-PROT at the EMBL Outstation –The European Bioinformatics Institute. Results from characterization experiments should also be submitted to SWISS-PROT at the EBI. This can include such information as function, subcellular location, subunit etc. Database contact/submission information:
email@example.com (for sequence submissions)
firstname.lastname@example.org (for characterization information)
Immunity, Inflammation and Disease supports the efforts to encourage open sharing of publication-related data. Immunity, Inflammation and Disease adheres to the beliefs that authors should include in their publications the data, algorithms, or other information that is central or integral to the publication or make it freely and readily accessible; use public repositories for data whenever possible; and make patented material available under a license for research use. For more information, see the NAS website: http://books.nap.edu/books/0309088593/html/1.html
For reports of epidemiological studies, authors should consult the STROBE initiative.
Authors of trials should adhere to the CONSORT reporting guidelines appropriate to their trial design.
Dual Use Research
Immunity, Inflammation and Disease expects that all authors will conform to the National Science Advisory Board for Biosecurity (NSABB) guidelines for Dual Use Life Sciences Research (http://oba.od.nih.gov/biosecurity/). For further information, and a description of ‘dual use research of concern’, please refer to the June 2007 NSABB report (http://oba.od.nih.gov/biosecurity/pdf/Framework for transmittal 0807_Sept07.pdf). If any of the reported studies may fall in any of these categories, the Editor-in-Chief must be informed at the time of manuscript submission.
Distribution of Reagents, Strains and Materials
The publication of an article in Immunity, Inflammation and Disease is subject to the understanding that authors will distribute freely any strains, clones or antibodies described therein for use in academic research. Authors might wish to make their plasmid constructs available free of charge through Addgene (www.addgene.org).
The policy stems from the long-standing scientific principle that authenticity requires reproducibility. Publication in Immunity, Inflammation and Disease constitutes a de facto acceptance of this policy. Included are reagents that can be easily provided; specifically, nucleic acid sequences, cDNA and genomic clones, cell lines, strains and monoclonal antibody clones. Small amounts (sufficient for the replication of any in vitro work reported) of novel protein reagents are also considered easily transferable.
Although the Editors appreciate that many of the reagents mentioned in Immunity, Inflammation and Disease are proprietary or unique, neither condition is considered adequate grounds for deviation from this policy. Suitable material transfer agreements can be drawn up between the provider and requester, but if a reasonable request is turned down and submitted to the Editor-in-Chief, the corresponding author will be held accountable.
Immunity, Inflammation and Disease requires that all appropriate steps be taken in obtaining informed consent of any and all human and/or experimental animal subjects participating in the research comprising the manuscript submitted for review and possible publication. A statement indicating that the protocol and procedures employed were reviewed and approved by the appropriate institutional review committee must be included in the Methods section of the manuscript. For research involving recombinant DNA, containment facilities and guidelines should conform to those of the National Institutes of Health or corresponding institutions. For those investigators who do not have formal ethics review committees, the principles outlined in the Helsinki Declaration should be followed.
Immunity, Inflammation and Disease requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author’s objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to, patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker’s fees from a company. The existence of a conflict of interest does not preclude publication in this journal.
If the authors have no conflict of interest to declare, they must also state this at submission.
It is the responsibility of the corresponding author to review this policy with all authors and collectively to list on the cover letter to the Editor-in-Chief, in the manuscript (under the Acknowledgements section), and in the online submission system ALL pertinent commercial and other relationships.
Search Engine Optimization for Your Paper
Please consult our SEO Tips for Authors page in order to maximize online discoverability for your published research. Included are tips for making your title and abstract SEO-friendly, choosing appropriate keywords, and promoting your research through social media.
CrossCheck is a multi-publisher initiative to screen published and submitted content using iThenticate. To find out more about CrossCheck visit http://www.crossref.org/crosscheck.html. By submitting your manuscript to Immunity, Inflammation and Disease you accept that your manuscript may be screened, using the iThenticate tool, for textual similarity to other previously published works.
Soon after acceptance, you will receive an email containing your PDF proof. Once you have submitted your corrections, the production office will finalize the layout of your article for publication.
As this is an open access journal, you have free, unlimited access to your article online. However, if you wish to obtain printed reprints, these may be ordered online: http://offprint.cosprinters.com (email: email@example.com).
Please direct any questions regarding the production of your article to the Production Editor at IID3@wiley.com.